Alpha Teknova, Inc.: Business Overview, Financials & Competitive Analysis
Alpha Teknova produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, with primary products including pre-poured media plates for cell ...
Cyborg Score thesis
Specialty bioprocess reagents supplier with dual revenue model gaining traction in cell and gene therapy markets, but challenged...
Read the full analyst-debate transcript →Get the Latest Alpha Teknova, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAlpha Teknova, Inc. Overview
Pro stress-test →Alpha Teknova produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, with primary products including pre-poured media plates for cell growth and cloning, liquid microbial culture media, and molecular biology reagents. The company serves pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic research institutions.
Strategic Profile
Pro stress-test →Teknova emphasizes a steady "Lab Essentials" foundation and a higher-growth "Clinical Solutions" segment tied to therapies and diagnostics moving through clinical development. The company's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale.
Competitive Landscape
Pro stress-test →InVitria and Cytiva are identified competitors. Alpha Teknova competes in the specialized bioprocess reagents and custom media supply segment, serving companies developing cell therapies, gene therapies, and mRNA vaccines. Its competitive advantage stems from proprietary manufacturing processes enabling rapid, custom-made-to-order products at scale.
Industry Context
Alpha Teknova, Inc. operates in Cell Culture Products.
Key facts
Founded: 1996 · Headquarters: Hollister, California, US · Employees: 158 · Revenue: $41.8M trailing twelve months (as of June 2026); 2026 full-year guidance: $42-44M · Market cap: $225M (as of June 2026)